Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) has announced its participation in two virtual investor conferences. The Wells Fargo 2020 Virtual Healthcare Conference will be held on September 10 at 2:00 PM ET, followed by the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 4:10 PM ET. Live webcasts will be accessible on the company's website with replays available for two weeks. Sunesis focuses on developing targeted inhibitors for cancer, including SNS-510, currently in IND-enabling studies.

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.

Wells Fargo 2020 Virtual Healthcare Conference
Date: Thursday, September 10
Time: 2:00 PM Eastern Time

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 21
Time: 4:10 PM Eastern Time

Live webcasts of the events will be available on the Sunesis website at http://ir.sunesis.com. A replay of each will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib is completing a Phase 1b trial in patients with advanced B cell malignancies.

For additional information on Sunesis, please visit www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Investor and Media Inquiries:		Par Hyare
Maeve Conneighton		Sunesis Pharmaceuticals Inc.
Argot Partners		650-266-3784
212-600-1902

FAQ

What are the details of Sunesis Pharmaceuticals' upcoming conferences?

Sunesis Pharmaceuticals will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 10 at 2:00 PM ET, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 4:10 PM ET.

Where can I watch the live webcast for Sunesis Pharmaceuticals' events?

The live webcasts for Sunesis Pharmaceuticals' events can be accessed on their official website at http://ir.sunesis.com.

What is SNS-510 and its current development status?

SNS-510 is a first-in-class PDK1 inhibitor being developed by Sunesis Pharmaceuticals, currently in IND-enabling studies.

What is the focus of Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals specializes in developing novel targeted inhibitors for hematologic and solid cancers.